NTRK3 is altered in 3.03% of malignant solid tumor patients with NTRK3 Mutation present in 2.61% of all malignant solid tumor patients [4].

NTRK3 Mutation is an inclusion criterion in 8 clinical trials for malignant solid tumor, of which 5 are open and 3 are closed. Of the trials that contain NTRK3 Mutation and malignant solid tumor as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].

NTRK3 is altered in 5.73% of non-small cell lung carcinoma patients with NTRK3 Mutation present in 5.25% of all non-small cell lung carcinoma patients [4].

NTRK3 Mutation is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NTRK3 is altered in 2.72% of head and neck squamous cell carcinoma patients with NTRK3 Mutation present in 2.54% of all head and neck squamous cell carcinoma patients [4].

NTRK3 Mutation is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK3 is altered in 0.95% of multiple myeloma patients with NTRK3 Mutation present in 0.95% of all multiple myeloma patients [4].

NTRK3 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK3 is altered in 0.66% of lymphoma patients with NTRK3 Mutation present in 0.61% of all lymphoma patients [4].

NTRK3 Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NTRK3 Mutation and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

NTRK3 is altered in 0.61% of B-cell non-hodgkin lymphoma patients with NTRK3 Mutation present in 0.52% of all B-cell non-hodgkin lymphoma patients [4].

NTRK3 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK3 Mutation is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 Mutation and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NTRK3 Mutation is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 Mutation and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].